-
Eisai and Medivir’s Combo Therapy Advances in Liver Cancer with Positive Trial Results
•
Japanese pharmaceutical company Eisai’s (TYO: 4523) kinase inhibitor Lenvima (Lenvatinib), combined with Swedish partner Medivir’s (STO: MVIR) chemotherapy fostroxacitabine bralpamide (fostrox), has demonstrated positive outcomes in an open-label Phase Ib/IIa trial for advanced hepatocellular carcinoma (HCC), Medivir announced. Following last year’s encouraging early data, these results are expected to pave…
-
Medivir’s Fostrox in Combination with Lenvima Shows Promise in Phase IIa HCC Trial
•
Sweden-based Medivir (STO: MVIR) has released interim data from a Phase IIa trial evaluating the combination of its experimental drug fostrox with Japan partner Eisai’s (TYO: 4523) kinase inhibitor Lenvima (Lenvatinib) for the treatment of advanced hepatocellular carcinoma (HCC). The trial focuses on patients for whom current first- or second-line…
-
Medivir AB Receives Chinese Patent Approval for Liver Cancer Treatment Fostroxacitabine Bralpamide
•
Sweden-based Medivir AB (FRA: MVR0) has announced the approval of a patent in China for its fostroxacitabine bralpamide (fostrox) and its use in the treatment of liver cancer. The patent, which remains valid until 2035 with potential for extensions, is a significant milestone for Medivir, considering China’s large population of…
